Personalized Accelerated Chemoradiation for Lung Cancer
Official title: Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Run by Stanford University · NCT06080061 · Data updated 2026-11-12
This study is testing a new way to personalize radiation treatment for people with locally advanced lung cancer to see if it works better and is safe.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Stanford University Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Palo Alto, California and 1 other locations) |
| Status | Recruiting |
| Started | October 25, 2023 |
| Main results expected | November 2026 |
| Study ends | December 2026 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT06080061 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with documented lung cancer who are eligible for definitive therapy and have a good performance status.
✕Probably not a fit
Patients with contraindications to radiotherapy or systemic therapy, or those with certain advanced tumor characteristics, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of hypofractionated accelerated radiation therapy (HART) to treat patients with locally advanced lung cancer. It aims to personalize treatment based on the tumor's location and size, combining radiation with systemic therapy for enhanced effectiveness. The trial will assess the safety and efficacy of this approach in a Phase 1 setting, focusing on patients who meet specific eligibility criteria.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective and personalized approach to managing locally advanced lung cancer.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in using accelerated radiation therapy for cancer treatment, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically documented malignancy of the thorax including but not limited to non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy * ECOG performance status of 0-2 * PET/CT or CT Imaging of Thorax * Age ≥ 18 years old * Ability to understand and the willingness to personally sign the written IRB approved informed consent document * Estimated life expectancy of 12 weeks or longer Exclusion Criteria: * Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist * Age \< 18 years old * Diagnosis of interstitial pulmonary fibrosis * Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
Where it's running
-
Stanford University
Palo Alto, California, United States Recruiting -
Stanford Cancer Center South Bay
San Jose, California, United States Recruiting
Study contacts
- Principal investigator: Joseph A Jaoude, MD — Stanford University
- Study coordinator: Aastha Dubey
- Email: adubey7@stanford@stanford.edu
- Phone: 650-725-2084
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.